Artificial Oxygen Carriers - The New Doping Threat in Endurance Sport?

Maximal oxygen uptake is the major performance limiting factor in endurance sports. Sophisticated training methods have been developed to increase this variable. On the other hand, attempts have been made to improve maximal oxygen uptake by artificial means: blood doping and the misuse of recombinant human erythropoietin have beneficial effects on aerobic exercise capacity. Both methods have been banned by international sporting federations. A new class of substances might represent the next step of fraudulent improvement of the maximal oxygen uptake: artificial oxygen carriers, such as solutions based on recombinant, bovine or human hemoglobin and perfluorocarbon-emulsions have been shown to improve oxygen delivery to the muscle. Hemoglobin-based solutions improve aerobic exercise capacity in animal and human testing. Both substances have potentially lethal side effects including renal toxicity, increased systemic and pulmonary blood pressure and impairment of the immune system. Hemoglobin-based carriers can be detected in drug testing with routine laboratory tests based on the detection of free hemoglobin. Perfluorocarbon is not metabolized by the body and exhaled through the lung and can be measured with chromatography. No screening for these substances in drug tests has been performed so far. International sporting federations should be aware of this new, emerging doping threat.

[1]  H. Northoff,et al.  A SYSTEM ESTABLISHING COMPATIBILITY PROFILES FOR ARTIFICIAL OXYGEN CARRIERS AND OTHER SUBSTANCES , 2001 .

[2]  David T. Martin,et al.  Reticulocyte parameters as potential discriminators of recombinant human erythropoietin abuse in elite athletes. , 2000, International journal of sports medicine.

[3]  D. Spahn,et al.  Eliminating Blood Transfusions: New Aspects and Perspectives , 2000, Anesthesiology.

[4]  A. Greenburg,et al.  A phase I study of oxidized raffinose cross-linked human hemoglobin , 2000, Critical care medicine.

[5]  F. Lasne,et al.  Recombinant erythropoietin in urine , 2000, Nature.

[6]  J. Berridge,et al.  Randomized Trial of Diaspirin Cross-linked Hemoglobin Solution as an Alternative to Blood Transfusion after Cardiac Surgery , 2000, Anesthesiology.

[7]  P. Buehler,et al.  Purification and chemical modifications of hemoglobin in developing hemoglobin based oxygen carriers. , 2000, Advanced drug delivery reviews.

[8]  D. Spahn,et al.  Current status of artificial oxygen carriers. , 2000, Advanced drug delivery reviews.

[9]  A. Gulati,et al.  Current aspects in pharmacology of modified hemoglobins. , 2000, Advanced drug delivery reviews.

[10]  O. Habler,et al.  Tissue perfusion and oxygenation with blood substitutes. , 2000, Advanced drug delivery reviews.

[11]  L. V. von Segesser,et al.  Blood Profile during and after Hemoglobin Substitute Administration , 2000, The International journal of artificial organs.

[12]  D. Gens,et al.  Diaspirin Cross-Linked Hemoglobin (DCLHb) in the Treatment of Severe Traumatic Hemorrhagic Shock: A Randomized Controlled Efficacy Trial , 1999 .

[13]  F. Bressolle,et al.  Effects of erythropoietin administration in training athletes and possible indirect detection in doping control. , 1999, Medicine and science in sports and exercise.

[14]  A. Burlingame,et al.  Structural characterization of human hemoglobin crosslinked by bis(3,5‐dibromosalicyl) fumarate using mass spectrometric techniques , 1997, Protein science : a publication of the Protein Society.

[15]  W. Sibbald,et al.  Diaspirin crosslinked hemoglobin improves systemic oxygen uptake in oxygen supply-dependent septic rats. , 1997, American journal of respiratory and critical care medicine.

[16]  D. Bailey,et al.  Physiological implications of altitude training for endurance performance at sea level: a review. , 1997, British journal of sports medicine.

[17]  M. Wolfson,et al.  Analysis of perfluorochemical elimination from the respiratory system. , 1997, Journal of applied physiology.

[18]  K. Messmer,et al.  Effects of diaspirin-cross-linked hemoglobin (DCLHb) on local tissue oxygen tension in striated skin muscle: an efficacy study in the hamster. , 1997, The Journal of laboratory and clinical medicine.

[19]  D. Callas,et al.  In vitro effects of a novel hemoglobin-based oxygen carrier on routine chemistry, therapeutic drug, coagulation, hematology, and blood bank assays. , 1997, Clinical chemistry.

[20]  A. Bodenham,et al.  Initial evaluation of diaspirin cross-linked hemoglobin (DCLHb) as a vasopressor in critically ill patients. , 1997, Critical care medicine.

[21]  E. Kochs,et al.  Haemodynamic changes and skeletal muscle oxygen tension during complete blood exchange with ultrapurified polymerized bovine haemoglobin , 1997, Intensive Care Medicine.

[22]  B D Levine,et al.  "Living high-training low": effect of moderate-altitude acclimatization with low-altitude training on performance. , 1997, Journal of applied physiology.

[23]  J. Schulte am Esch,et al.  Bovine hemoglobin increases skeletal muscle oxygenation during 95% artificial arterial stenosis. , 1997, Surgery.

[24]  C. Otto,et al.  Initial experience with partial liquid ventilation in adult patients with the acute respiratory distress syndrome. , 1996, JAMA.

[25]  W. Colburn,et al.  Phase I study of the safety and pharmacologic effects of diaspirin cross-linked hemoglobin solution. , 1996, Critical care medicine.

[26]  M. Sawka,et al.  American College of Sports Medicine position stand. The use of blood doping as an ergogenic aid. , 1996, Medicine and science in sports and exercise.

[27]  G. S. Hughes,et al.  Hemoglobin‐based oxygen carrier preserves submaximal exercise capacity in humans , 1995, Clinical pharmacology and therapeutics.

[28]  RUTH E. Benesch,et al.  Hemoglobin tetramers stabilized by a single intramolecular cross-link , 1991, Journal of protein chemistry.

[29]  B. Ekblom,et al.  Effect of erythropoietin administration on mammal aerobic power , 1991 .

[30]  W. Odling‐Smee ABC of transfusion. Red cell substitutes. , 1990, BMJ.

[31]  B. Berglund,et al.  Effect of reinfusion of autologous blood on exercise performance in cross-country skiers. , 1987, International journal of sports medicine.

[32]  J. Lafortune,et al.  Renal vascular effects of stroma and stroma-free hemoglobin. , 1979, Surgical forum.

[33]  B. Ekblom,et al.  Response to exercise after blood loss and reinfusion. , 1972, Journal of applied physiology.

[34]  B. Saltin,et al.  Maximal oxygen uptake in athletes. , 1967, Journal of applied physiology.

[35]  R. Winslow Safety and utility of blood substitutes. , 2000, Developments in Biologicals.

[36]  P. Keipert,et al.  Randomized safety studies of intravenous perflubron emulsion. II. Effects on immune function in healthy volunteers. , 2000, Anesthesia and analgesia.

[37]  C J Gore,et al.  A novel method utilising markers of altered erythropoiesis for the detection of recombinant human erythropoietin abuse in athletes. , 2000, Haematologica.

[38]  R. Winslow New transfusion strategies: red cell substitutes. , 1999, Annual review of medicine.

[39]  M. Lamy,et al.  Red blood cell substitutes: fluorocarbon emulsions and haemoglobin solutions. , 1999, British medical bulletin.

[40]  J. Baron Haemoglobin therapy in clinical practice: use and characteristics of DCLHb. , 1998, British journal of anaesthesia.

[41]  R. Winslow,et al.  Fluid resuscitation with O2 vs. non-O2 carriers after 2 h of hemorrhagic shock in conscious hamsters. , 1997, The American journal of physiology.

[42]  J. Hess Blood substitutes. , 1996, Seminars in hematology.

[43]  P. Keipert Use of Oxygent, a perfluorochemical-based oxygen carrier, as an alternative to intraoperative blood transfusion. , 1995, Artificial cells, blood substitutes, and immobilization biotechnology.

[44]  G. Evans,et al.  Initial clinical experience with a rationally designed, genetically engineered recombinant human hemoglobin. , 1994, Artificial cells, blood substitutes, and immobilization biotechnology.

[45]  S. Flaim Pharmacokinetics and side effects of perfluorocarbon-based blood substitutes. , 1994, Artificial cells, blood substitutes, and immobilization biotechnology.

[46]  N. Afonin,et al.  The elimination peculiarities of perfluorocarbon emulsions stabilized with egg yolk phospholipid. , 1994, Artificial cells, blood substitutes, and immobilization biotechnology.

[47]  D. L. Parsons,et al.  Perfluorochemical erythrocyte substitutes: disposition and effects on drug distribution and elimination. , 1991, Drug metabolism reviews.